Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’

By afschroeder • July 10, 2026

Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van Cutsem E, Bekaii-Saab T, Zhang L, Li J, Chen H, Maxwell F, Wainberg ZA, Melisi D. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial'. ESMO Open. 2026 Jul 9;11(8):108307. doi: 10.1016/j.esmoop.2026.108307. Epub ahead of print. PMID: 42424906.

Tags: Hematology/Oncology, Publications

Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety-Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024

Zheng D, Nold T, Ramakrishnan N, Kim K, Tomassetti S. Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles[...]

Evolution and heterogeneity of lethal metastatic bladder cancer subtypes

Itagi P, Schuster SL, Arora S, Persse TW, Waters JA, Yang M, Min A, Chandra P, Adil M, Galipeau PC, Rudoy D, Kreitman AS, Lin[...]

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

Wu YL, Majem M, John T, Grohé C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov[...]